In EDS ansehen

Postoperative Adjuvant Transcatheterarterial Chemoembolization Should Be Considered Selectively for Patients with Cytokeratin-19 Positive Hepatocellular Carcinoma

Gespeichert in:
Bibliographische Detailangaben
Titel: Postoperative Adjuvant Transcatheterarterial Chemoembolization Should Be Considered Selectively for Patients with Cytokeratin-19 Positive Hepatocellular Carcinoma
Autoren: Mai RY, Tao Z, Huang HY, Zeng C, Mo KX, Zeng DD, Liang R, Lin Y, Wang XB, Bai T, Li LQ, Ye JZ, Wu GB
Quelle: Journal of Hepatocellular Carcinoma, Vol 12, Iss Issue 1, Pp 2407-2419 (2025)
Verlagsinformationen: Dove Medical Press, 2025.
Publikationsjahr: 2025
Bestand: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Schlagwörter: hepatocellular carcinoma, hepatectomy, Cytokeratin 19, postoperative adjuvant transarterial chemoembolization, recurrence-free survival, overall survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Beschreibung: Rong-Yun Mai,1,* Zheng Tao,1,* Hong-Yang Huang,1,* Can Zeng,1 Kai-Xiang Mo,1 Dan-Dan Zeng,2 Rong Liang,2 Yan Lin,2 Xiao-Bo Wang,1 Tao Bai,1 Le-Qun Li,1 Jia-Zhou Ye,1 Guo-Bin Wu1 1Department of Hepatobiliary & Pancreatic Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, People’s Republic of China; 2Department of Digestive Oncology, Guangxi Medical University Cancer Hospital, Nanning, 530021, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jia-Zhou Ye; Guo-Bin Wu, Department of Hepatobilliary & Pancreatic Surgery, Guangxi Medical University Cancer Hospital, 71 He Di Road, Nanning, 530021, People’s Republic of China, Email yejiazhou@gxmu.edu.cn; wuguobin@gxmu.edu.cnBackground: This study aimed to evaluate the clinical efficacy of postoperative adjuvant transarterial chemoembolization (PA-TACE) in cytokeratin 19-positive (CK19+) hepatocellular carcinoma (HCC) patients and to identify cases that may benefit from PA-TACE.Methods: We conducted a retrospective analysis of 453 CK19+ HCC patients who underwent hepatectomy between November 2013 and June 2019 at our institution. We compared the recurrence-free survival (RFS) and overall survival (OS) between patients who received PA-TACE and those who did not, utilizing propensity score matching (PSM) to balance the groups.Results: Before and after PSM, both RFS and OS were significantly greater in PA-TACE group compared to the non-TACE group. Multivariable analysis identified PA-TACE as a significantly favorable factor of RFS and OS. In subgroups analyses, PA-TACE significantly improved RFS and OS in patients with CK19+ HCC under the following conditions: alpha-fetoprotein ≥ 400 ng/mL, cirrhosis, tumor size ≥ 5 cm, multiple tumors, major resection, Edmondson-Steiner stage III–IV, macrovascular invasion and microvascular invasion. Similar results were obtained in patients with higher tumor stages. Further recurrence model analyses revealed that PA-TACE significantly reduced early recurrence in patients with high-risk of postoperative recurrence, but had little effect on late recurrence.Conclusion: Among CK19+ HCC patients with higher recurrence of postoperative risk, PA-TACE could greatly improve RFS and OS.Keywords: hepatocellular carcinoma, hepatectomy, cytokeratin 19, postoperative adjuvant transarterial chemoembolization, recurrence-free survival, overall survival
Publikationsart: article
Dateibeschreibung: electronic resource
Sprache: English
ISSN: 2253-5969
Relation: https://www.dovepress.com/postoperative-adjuvant-transcatheterarterial-chemoembolization-should--peer-reviewed-fulltext-article-JHC; https://doaj.org/toc/2253-5969
Zugangs-URL: https://doaj.org/article/213080b28d8b48eab77b6a0b9e36e36c
Dokumentencode: edsdoj.213080b28d8b48eab77b6a0b9e36e36c
Datenbank: Directory of Open Access Journals
Beschreibung
Abstract:Rong-Yun Mai,1,* Zheng Tao,1,* Hong-Yang Huang,1,* Can Zeng,1 Kai-Xiang Mo,1 Dan-Dan Zeng,2 Rong Liang,2 Yan Lin,2 Xiao-Bo Wang,1 Tao Bai,1 Le-Qun Li,1 Jia-Zhou Ye,1 Guo-Bin Wu1 1Department of Hepatobiliary & Pancreatic Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, People’s Republic of China; 2Department of Digestive Oncology, Guangxi Medical University Cancer Hospital, Nanning, 530021, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jia-Zhou Ye; Guo-Bin Wu, Department of Hepatobilliary & Pancreatic Surgery, Guangxi Medical University Cancer Hospital, 71 He Di Road, Nanning, 530021, People’s Republic of China, Email yejiazhou@gxmu.edu.cn; wuguobin@gxmu.edu.cnBackground: This study aimed to evaluate the clinical efficacy of postoperative adjuvant transarterial chemoembolization (PA-TACE) in cytokeratin 19-positive (CK19+) hepatocellular carcinoma (HCC) patients and to identify cases that may benefit from PA-TACE.Methods: We conducted a retrospective analysis of 453 CK19+ HCC patients who underwent hepatectomy between November 2013 and June 2019 at our institution. We compared the recurrence-free survival (RFS) and overall survival (OS) between patients who received PA-TACE and those who did not, utilizing propensity score matching (PSM) to balance the groups.Results: Before and after PSM, both RFS and OS were significantly greater in PA-TACE group compared to the non-TACE group. Multivariable analysis identified PA-TACE as a significantly favorable factor of RFS and OS. In subgroups analyses, PA-TACE significantly improved RFS and OS in patients with CK19+ HCC under the following conditions: alpha-fetoprotein ≥ 400 ng/mL, cirrhosis, tumor size ≥ 5 cm, multiple tumors, major resection, Edmondson-Steiner stage III–IV, macrovascular invasion and microvascular invasion. Similar results were obtained in patients with higher tumor stages. Further recurrence model analyses revealed that PA-TACE significantly reduced early recurrence in patients with high-risk of postoperative recurrence, but had little effect on late recurrence.Conclusion: Among CK19+ HCC patients with higher recurrence of postoperative risk, PA-TACE could greatly improve RFS and OS.Keywords: hepatocellular carcinoma, hepatectomy, cytokeratin 19, postoperative adjuvant transarterial chemoembolization, recurrence-free survival, overall survival
ISSN:22535969